| Price and Chart delayed at least 15 mintues. |
|
Price
$ 27.47
|
Change
0.00
|
|
Open
0.00
|
% Change
0.0%
|
|
Prev Close
27.47
|
Volume
NA
|
|
Market Value
2 bil
|
P/E Ratio
3.9
|
|
Bid
27.10
|
EPS
7.07
|
|
Ask
27.84
|
Dividend
0.00
|
|
High
0.00
|
Yield
0.0
|
|
Low
0.00
|
Shares Out
58 mil
|
|
52wk High
53.71
|
52wk Low
27.01
|
|
Industry: Biotechnology
|
|
Sector: Healthcare
|
OSIP Profile
A biotechnology company committed to building a top tier biopharmaceutical organization that discovers, develops and commercializes innovative molecular targeted therapies addressing major unmet medical needs in oncology, diabetes and obesity.
OSI Pharm Inc
41 Pinelawn Road
Melville, NY 11747
Phone: (631) 962-2000
Fax: (631) 752-3880
Web Site: www.osip.com
OSIP Wires Headlines
|
|
| 07.01.09 |
|
UPDATE 1-Europe approves AstraZeneca lung cancer drug
|
|
| 06.15.09 |
|
BRIEF-OSI Pharmaceuticals says FDA accepts Tarceva sNDA for review
|
More OSIP From Wires Headlines >
Forbes.com on OSIP RSS
No news found in the past 30 days.OSIP Press Releases
|
|
| 06.15.09 |
|
OSI Pharmaceuticals Announces Acceptance of Tarceva Supplemental New Drug Application for... |
More OSIP Press Releases >
OSIP Ratios & Returns
| Price-to-sales |
4.16 |
| Return on Equity |
20.1 |
| Operating Margin |
38.3 |
| Profit Margin |
32.8% |
More OSIP Ratios & Returns >
OSIP Financials
| Sales |
382.33 mil |
| Profits |
125.357 mil |
| Assets |
$1.085145 bil |
| Employees |
491.0 |
|
|
|
OSI Pharmaceuticals is ranked # 1961 on the 2009 Forbes 2000 List
|
|
Thomson / IBES Earnings Estimates on OSIP
Accounting Risk
Buy/Hold/Sell Analysis
Forbes Investment Guru Commentary on OSIP
RSS News Feed on OSIP
|
A D V E R T I S E M E N T
|